There was a reduction in TGF-β1 in the olmesartan treated group but not in hepatic fibrosis markers which include serum hyaluronic acid, type IV collagen, and procollagen III N-terminal propeptide levels [55]. Here, TGFB1 is linked to Hepatic fibrosis.